Biophysical Validation of Serotonin 5-HT2A and 5-HT2C Receptor Interaction
Overview
Authors
Affiliations
The serotonin (5-HT) 5-HT2A receptor (5-HT2AR) and 5-HT2C receptor (5-HT2CR) in the central nervous system are implicated in a range of normal behaviors (e.g., appetite, sleep) and physiological functions (e.g., endocrine secretion) while dysfunctional 5-HT2AR and/or 5-HT2CR are implicated in neuropsychiatric disorders (e.g., addiction, obesity, schizophrenia). Preclinical studies suggest that the 5-HT2AR and 5-HT2CR may act in concert to regulate the neural bases for behavior. Here, we utilize three distinct biophysical and immunocytochemistry-based approaches to identify and study this receptor complex in cultured cells. Employing a split luciferase complementation assay (LCA), we demonstrated that formation of the 5-HT2AR:5-HT2CR complex exists within 50 nm, increases proportionally to the 5-HT2CR:5-HT2AR protein expression ratio, and is specific to the receptor interaction and not due to random complementation of the luciferase fragments. Using a proximity ligation assay (PLA), we found that cells stably expressing both the 5-HT2AR and 5-HT2CR exhibit 5-HT2AR:5-HT2CR heteroreceptor complexes within 40 nm of each other. Lastly, bioluminescence resonance energy transfer (BRET) analyses indicates the formation of a specific and saturable 5-HT2AR:5-HT2CR interaction, suggesting that the 5-HT2AR and 5-HT2CR form a close interaction within 10 nm of each other in intact live cells. The bioengineered receptors generated for the LCA and the BRET exhibit 5-HT-mediated intracellular calcium signaling as seen for the native receptors. Taken together, this study validates a very close 5-HT2AR:5-HT2CR interaction in cultured cells.
Zhang J, Gao L, Yang G, Kong D Front Endocrinol (Lausanne). 2024; 15:1369676.
PMID: 38745947 PMC: 11091366. DOI: 10.3389/fendo.2024.1369676.
Elsadek L, Ellis E, Seabra G, Paul V, Luesch H Mar Drugs. 2024; 22(1).
PMID: 38248654 PMC: 10817531. DOI: 10.3390/md22010028.
μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges.
Salinsky L, Merritt C, Zamora J, Giacomini J, Anastasio N, Cunningham K Front Pharmacol. 2023; 14:1239159.
PMID: 37886127 PMC: 10598667. DOI: 10.3389/fphar.2023.1239159.
Sathe P, Ramdasi G, Giammatteo K, Beauzile H, Wang S, Zhang H Pharmacol Res Perspect. 2023; 11(5):e01144.
PMID: 37837184 PMC: 10576165. DOI: 10.1002/prp2.1144.
Chen J, Garcia E, Merritt C, Zamora J, Bolinger A, Pazdrak K J Med Chem. 2023; 66(14):9992-10009.
PMID: 37462530 PMC: 10853020. DOI: 10.1021/acs.jmedchem.3c00908.